

Global Pulmonary Drugs Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G774C055964FEN.html>

Date: September 2024

Pages: 166

Price: US\$ 3,200.00 (Single User License)

ID: G774C055964FEN

Abstracts

Report Overview

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such as asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

The global Pulmonary Drugs market size was estimated at USD 41400 million in 2023 and is projected to reach USD 70493.72 million by 2030, exhibiting a CAGR of 7.90% during the forecast period.

North America Pulmonary Drugs market size was USD 10787.66 million in 2023, at a CAGR of 6.77% during the forecast period of 2024 through 2030.

This report provides a deep insight into the global Pulmonary Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pulmonary Drugs Market, this report introduces in detail the market share,

market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pulmonary Drugs market in any manner.

Global Pulmonary Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Sanofi SA

Meda Pharmaceuticals

Circassia Pharmaceuticals Plc.

AstraZeneca Plc.

GlaxoSmithKline Plc.

Mallinckrodt Pharmaceuticals Plc.

Cheisi Farmaceutici S.p.A

Zambon Company S.p.A

Alaxia SAS

Merck Sharp & Dohme Limited

Boehringer Ingelheim

Grifols

S.A.

Abbott Laboratories

AbbVie Inc.

Aerogen Pharma Ltd.

Aurobindo Pharma Ltd.

Celon Pharma SA

Cipla Ltd.

F. Hoffmann La Roche Ltd.

Glenmark Pharmaceuticals Ltd.

Lupin Ltd.

Medisol Lifescience Pvt. Ltd.

Novartis AG

Sumitomo Pharma Co. Ltd.

Teva Pharmaceutical Industries Ltd.

Vertex Pharmaceuticals Inc.

Wellona Pharma

Market Segmentation (by Type)

Inhaled Corticosteroids

Long Acting Beta-2 Agonists

Antihistamines

Vasodilators

Others

Market Segmentation (by Application)

Asthma & COPD

Allergic Rhinitis

Pulmonary Arterial Hypertension

Cystic Fibrosis

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Pulmonary Drugs Market

Overview of the regional outlook of the Pulmonary Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pulmonary Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the

market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Pulmonary Drugs
- 1.2 Key Market Segments
 - 1.2.1 Pulmonary Drugs Segment by Type
 - 1.2.2 Pulmonary Drugs Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 PULMONARY DRUGS MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Pulmonary Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
 - 2.1.2 Global Pulmonary Drugs Sales Estimates and Forecasts (2019-2030)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 PULMONARY DRUGS MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Pulmonary Drugs Sales by Manufacturers (2019-2024)
- 3.2 Global Pulmonary Drugs Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Pulmonary Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Pulmonary Drugs Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Pulmonary Drugs Sales Sites, Area Served, Product Type
- 3.6 Pulmonary Drugs Market Competitive Situation and Trends
 - 3.6.1 Pulmonary Drugs Market Concentration Rate
 - 3.6.2 Global 5 and 10 Largest Pulmonary Drugs Players Market Share by Revenue
 - 3.6.3 Mergers & Acquisitions, Expansion

4 PULMONARY DRUGS INDUSTRY CHAIN ANALYSIS

- 4.1 Pulmonary Drugs Industry Chain Analysis

- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PULMONARY DRUGS MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 PULMONARY DRUGS MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Pulmonary Drugs Sales Market Share by Type (2019-2024)
- 6.3 Global Pulmonary Drugs Market Size Market Share by Type (2019-2024)
- 6.4 Global Pulmonary Drugs Price by Type (2019-2024)

7 PULMONARY DRUGS MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Pulmonary Drugs Market Sales by Application (2019-2024)
- 7.3 Global Pulmonary Drugs Market Size (M USD) by Application (2019-2024)
- 7.4 Global Pulmonary Drugs Sales Growth Rate by Application (2019-2024)

8 PULMONARY DRUGS MARKET SEGMENTATION BY REGION

- 8.1 Global Pulmonary Drugs Sales by Region
 - 8.1.1 Global Pulmonary Drugs Sales by Region
 - 8.1.2 Global Pulmonary Drugs Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Pulmonary Drugs Sales by Country
 - 8.2.2 U.S.

- 8.2.3 Canada
- 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Pulmonary Drugs Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Pulmonary Drugs Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Pulmonary Drugs Sales by Country
 - 8.5.2 Brazil
 - 8.5.3 Argentina
 - 8.5.4 Columbia
- 8.6 Middle East and Africa
 - 8.6.1 Middle East and Africa Pulmonary Drugs Sales by Region
 - 8.6.2 Saudi Arabia
 - 8.6.3 UAE
 - 8.6.4 Egypt
 - 8.6.5 Nigeria
 - 8.6.6 South Africa

9 KEY COMPANIES PROFILE

- 9.1 Sanofi SA
 - 9.1.1 Sanofi SA Pulmonary Drugs Basic Information
 - 9.1.2 Sanofi SA Pulmonary Drugs Product Overview
 - 9.1.3 Sanofi SA Pulmonary Drugs Product Market Performance
 - 9.1.4 Sanofi SA Business Overview
 - 9.1.5 Sanofi SA Pulmonary Drugs SWOT Analysis
 - 9.1.6 Sanofi SA Recent Developments
- 9.2 Meda Pharmaceuticals

- 9.2.1 Meda Pharmaceuticals Pulmonary Drugs Basic Information
- 9.2.2 Meda Pharmaceuticals Pulmonary Drugs Product Overview
- 9.2.3 Meda Pharmaceuticals Pulmonary Drugs Product Market Performance
- 9.2.4 Meda Pharmaceuticals Business Overview
- 9.2.5 Meda Pharmaceuticals Pulmonary Drugs SWOT Analysis
- 9.2.6 Meda Pharmaceuticals Recent Developments
- 9.3 Circassia Pharmaceuticals Plc.
 - 9.3.1 Circassia Pharmaceuticals Plc. Pulmonary Drugs Basic Information
 - 9.3.2 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Overview
 - 9.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Market Performance
 - 9.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
 - 9.3.5 Circassia Pharmaceuticals Plc. Business Overview
 - 9.3.6 Circassia Pharmaceuticals Plc. Recent Developments
- 9.4 AstraZeneca Plc.
 - 9.4.1 AstraZeneca Plc. Pulmonary Drugs Basic Information
 - 9.4.2 AstraZeneca Plc. Pulmonary Drugs Product Overview
 - 9.4.3 AstraZeneca Plc. Pulmonary Drugs Product Market Performance
 - 9.4.4 AstraZeneca Plc. Business Overview
 - 9.4.5 AstraZeneca Plc. Recent Developments
- 9.5 GlaxoSmithKline Plc.
 - 9.5.1 GlaxoSmithKline Plc. Pulmonary Drugs Basic Information
 - 9.5.2 GlaxoSmithKline Plc. Pulmonary Drugs Product Overview
 - 9.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product Market Performance
 - 9.5.4 GlaxoSmithKline Plc. Business Overview
 - 9.5.5 GlaxoSmithKline Plc. Recent Developments
- 9.6 Mallinckrodt Pharmaceuticals Plc.
 - 9.6.1 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Basic Information
 - 9.6.2 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Overview
 - 9.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Market Performance
 - 9.6.4 Mallinckrodt Pharmaceuticals Plc. Business Overview
 - 9.6.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
- 9.7 Cheisi Farmaceutici S.p.A
 - 9.7.1 Cheisi Farmaceutici S.p.A Pulmonary Drugs Basic Information
 - 9.7.2 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Overview
 - 9.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Market Performance
 - 9.7.4 Cheisi Farmaceutici S.p.A Business Overview
 - 9.7.5 Cheisi Farmaceutici S.p.A Recent Developments
- 9.8 Zambon Company S.p.A

- 9.8.1 Zambon Company S.p.A Pulmonary Drugs Basic Information
- 9.8.2 Zambon Company S.p.A Pulmonary Drugs Product Overview
- 9.8.3 Zambon Company S.p.A Pulmonary Drugs Product Market Performance
- 9.8.4 Zambon Company S.p.A Business Overview
- 9.8.5 Zambon Company S.p.A Recent Developments
- 9.9 Alaxia SAS
 - 9.9.1 Alaxia SAS Pulmonary Drugs Basic Information
 - 9.9.2 Alaxia SAS Pulmonary Drugs Product Overview
 - 9.9.3 Alaxia SAS Pulmonary Drugs Product Market Performance
 - 9.9.4 Alaxia SAS Business Overview
 - 9.9.5 Alaxia SAS Recent Developments
- 9.10 Merck Sharp and Dohme Limited
 - 9.10.1 Merck Sharp and Dohme Limited Pulmonary Drugs Basic Information
 - 9.10.2 Merck Sharp and Dohme Limited Pulmonary Drugs Product Overview
 - 9.10.3 Merck Sharp and Dohme Limited Pulmonary Drugs Product Market Performance
 - 9.10.4 Merck Sharp and Dohme Limited Business Overview
 - 9.10.5 Merck Sharp and Dohme Limited Recent Developments
- 9.11 Boehringer Ingelheim
 - 9.11.1 Boehringer Ingelheim Pulmonary Drugs Basic Information
 - 9.11.2 Boehringer Ingelheim Pulmonary Drugs Product Overview
 - 9.11.3 Boehringer Ingelheim Pulmonary Drugs Product Market Performance
 - 9.11.4 Boehringer Ingelheim Business Overview
 - 9.11.5 Boehringer Ingelheim Recent Developments
- 9.12 Grifols
 - 9.12.1 Grifols Pulmonary Drugs Basic Information
 - 9.12.2 Grifols Pulmonary Drugs Product Overview
 - 9.12.3 Grifols Pulmonary Drugs Product Market Performance
 - 9.12.4 Grifols Business Overview
 - 9.12.5 Grifols Recent Developments
- 9.13 S.A.
 - 9.13.1 S.A. Pulmonary Drugs Basic Information
 - 9.13.2 S.A. Pulmonary Drugs Product Overview
 - 9.13.3 S.A. Pulmonary Drugs Product Market Performance
 - 9.13.4 S.A. Business Overview
 - 9.13.5 S.A. Recent Developments
- 9.14 Abbott Laboratories
 - 9.14.1 Abbott Laboratories Pulmonary Drugs Basic Information
 - 9.14.2 Abbott Laboratories Pulmonary Drugs Product Overview

- 9.14.3 Abbott Laboratories Pulmonary Drugs Product Market Performance
- 9.14.4 Abbott Laboratories Business Overview
- 9.14.5 Abbott Laboratories Recent Developments
- 9.15 AbbVie Inc.
 - 9.15.1 AbbVie Inc. Pulmonary Drugs Basic Information
 - 9.15.2 AbbVie Inc. Pulmonary Drugs Product Overview
 - 9.15.3 AbbVie Inc. Pulmonary Drugs Product Market Performance
 - 9.15.4 AbbVie Inc. Business Overview
 - 9.15.5 AbbVie Inc. Recent Developments
- 9.16 Aerogen Pharma Ltd.
 - 9.16.1 Aerogen Pharma Ltd. Pulmonary Drugs Basic Information
 - 9.16.2 Aerogen Pharma Ltd. Pulmonary Drugs Product Overview
 - 9.16.3 Aerogen Pharma Ltd. Pulmonary Drugs Product Market Performance
 - 9.16.4 Aerogen Pharma Ltd. Business Overview
 - 9.16.5 Aerogen Pharma Ltd. Recent Developments
- 9.17 Aurobindo Pharma Ltd.
 - 9.17.1 Aurobindo Pharma Ltd. Pulmonary Drugs Basic Information
 - 9.17.2 Aurobindo Pharma Ltd. Pulmonary Drugs Product Overview
 - 9.17.3 Aurobindo Pharma Ltd. Pulmonary Drugs Product Market Performance
 - 9.17.4 Aurobindo Pharma Ltd. Business Overview
 - 9.17.5 Aurobindo Pharma Ltd. Recent Developments
- 9.18 Celon Pharma SA
 - 9.18.1 Celon Pharma SA Pulmonary Drugs Basic Information
 - 9.18.2 Celon Pharma SA Pulmonary Drugs Product Overview
 - 9.18.3 Celon Pharma SA Pulmonary Drugs Product Market Performance
 - 9.18.4 Celon Pharma SA Business Overview
 - 9.18.5 Celon Pharma SA Recent Developments
- 9.19 Cipla Ltd.
 - 9.19.1 Cipla Ltd. Pulmonary Drugs Basic Information
 - 9.19.2 Cipla Ltd. Pulmonary Drugs Product Overview
 - 9.19.3 Cipla Ltd. Pulmonary Drugs Product Market Performance
 - 9.19.4 Cipla Ltd. Business Overview
 - 9.19.5 Cipla Ltd. Recent Developments
- 9.20 F. Hoffmann La Roche Ltd.
 - 9.20.1 F. Hoffmann La Roche Ltd. Pulmonary Drugs Basic Information
 - 9.20.2 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Overview
 - 9.20.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Market Performance
 - 9.20.4 F. Hoffmann La Roche Ltd. Business Overview
 - 9.20.5 F. Hoffmann La Roche Ltd. Recent Developments

9.21 Glenmark Pharmaceuticals Ltd.

9.21.1 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Basic Information

9.21.2 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Overview

9.21.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Market Performance

9.21.4 Glenmark Pharmaceuticals Ltd. Business Overview

9.21.5 Glenmark Pharmaceuticals Ltd. Recent Developments

9.22 Lupin Ltd.

9.22.1 Lupin Ltd. Pulmonary Drugs Basic Information

9.22.2 Lupin Ltd. Pulmonary Drugs Product Overview

9.22.3 Lupin Ltd. Pulmonary Drugs Product Market Performance

9.22.4 Lupin Ltd. Business Overview

9.22.5 Lupin Ltd. Recent Developments

9.23 Medisol Lifescience Pvt. Ltd.

9.23.1 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Basic Information

9.23.2 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Overview

9.23.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Market Performance

9.23.4 Medisol Lifescience Pvt. Ltd. Business Overview

9.23.5 Medisol Lifescience Pvt. Ltd. Recent Developments

9.24 Novartis AG

9.24.1 Novartis AG Pulmonary Drugs Basic Information

9.24.2 Novartis AG Pulmonary Drugs Product Overview

9.24.3 Novartis AG Pulmonary Drugs Product Market Performance

9.24.4 Novartis AG Business Overview

9.24.5 Novartis AG Recent Developments

9.25 Sumitomo Pharma Co. Ltd.

9.25.1 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Basic Information

9.25.2 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Overview

9.25.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Market Performance

9.25.4 Sumitomo Pharma Co. Ltd. Business Overview

9.25.5 Sumitomo Pharma Co. Ltd. Recent Developments

9.26 Teva Pharmaceutical Industries Ltd.

9.26.1 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Basic Information

9.26.2 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Overview

9.26.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Market Performance

9.26.4 Teva Pharmaceutical Industries Ltd. Business Overview

9.26.5 Teva Pharmaceutical Industries Ltd. Recent Developments

9.27 Vertex Pharmaceuticals Inc.

9.27.1 Vertex Pharmaceuticals Inc. Pulmonary Drugs Basic Information

- 9.27.2 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Overview
- 9.27.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Market Performance
- 9.27.4 Vertex Pharmaceuticals Inc. Business Overview
- 9.27.5 Vertex Pharmaceuticals Inc. Recent Developments
- 9.28 Wellona Pharma
 - 9.28.1 Wellona Pharma Pulmonary Drugs Basic Information
 - 9.28.2 Wellona Pharma Pulmonary Drugs Product Overview
 - 9.28.3 Wellona Pharma Pulmonary Drugs Product Market Performance
 - 9.28.4 Wellona Pharma Business Overview
 - 9.28.5 Wellona Pharma Recent Developments

10 PULMONARY DRUGS MARKET FORECAST BY REGION

- 10.1 Global Pulmonary Drugs Market Size Forecast
- 10.2 Global Pulmonary Drugs Market Forecast by Region
 - 10.2.1 North America Market Size Forecast by Country
 - 10.2.2 Europe Pulmonary Drugs Market Size Forecast by Country
 - 10.2.3 Asia Pacific Pulmonary Drugs Market Size Forecast by Region
 - 10.2.4 South America Pulmonary Drugs Market Size Forecast by Country
 - 10.2.5 Middle East and Africa Forecasted Consumption of Pulmonary Drugs by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

- 11.1 Global Pulmonary Drugs Market Forecast by Type (2025-2030)
 - 11.1.1 Global Forecasted Sales of Pulmonary Drugs by Type (2025-2030)
 - 11.1.2 Global Pulmonary Drugs Market Size Forecast by Type (2025-2030)
 - 11.1.3 Global Forecasted Price of Pulmonary Drugs by Type (2025-2030)
- 11.2 Global Pulmonary Drugs Market Forecast by Application (2025-2030)
 - 11.2.1 Global Pulmonary Drugs Sales (Kilotons) Forecast by Application
 - 11.2.2 Global Pulmonary Drugs Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Pulmonary Drugs Market Size Comparison by Region (M USD)
- Table 5. Global Pulmonary Drugs Sales (Kilotons) by Manufacturers (2019-2024)
- Table 6. Global Pulmonary Drugs Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Pulmonary Drugs Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Pulmonary Drugs Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Drugs as of 2022)
- Table 10. Global Market Pulmonary Drugs Average Price (USD/Ton) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Pulmonary Drugs Sales Sites and Area Served
- Table 12. Manufacturers Pulmonary Drugs Product Type
- Table 13. Global Pulmonary Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Pulmonary Drugs
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Pulmonary Drugs Market Challenges
- Table 22. Global Pulmonary Drugs Sales by Type (Kilotons)
- Table 23. Global Pulmonary Drugs Market Size by Type (M USD)
- Table 24. Global Pulmonary Drugs Sales (Kilotons) by Type (2019-2024)
- Table 25. Global Pulmonary Drugs Sales Market Share by Type (2019-2024)
- Table 26. Global Pulmonary Drugs Market Size (M USD) by Type (2019-2024)
- Table 27. Global Pulmonary Drugs Market Size Share by Type (2019-2024)
- Table 28. Global Pulmonary Drugs Price (USD/Ton) by Type (2019-2024)
- Table 29. Global Pulmonary Drugs Sales (Kilotons) by Application
- Table 30. Global Pulmonary Drugs Market Size by Application
- Table 31. Global Pulmonary Drugs Sales by Application (2019-2024) & (Kilotons)
- Table 32. Global Pulmonary Drugs Sales Market Share by Application (2019-2024)

- Table 33. Global Pulmonary Drugs Sales by Application (2019-2024) & (M USD)
- Table 34. Global Pulmonary Drugs Market Share by Application (2019-2024)
- Table 35. Global Pulmonary Drugs Sales Growth Rate by Application (2019-2024)
- Table 36. Global Pulmonary Drugs Sales by Region (2019-2024) & (Kilotons)
- Table 37. Global Pulmonary Drugs Sales Market Share by Region (2019-2024)
- Table 38. North America Pulmonary Drugs Sales by Country (2019-2024) & (Kilotons)
- Table 39. Europe Pulmonary Drugs Sales by Country (2019-2024) & (Kilotons)
- Table 40. Asia Pacific Pulmonary Drugs Sales by Region (2019-2024) & (Kilotons)
- Table 41. South America Pulmonary Drugs Sales by Country (2019-2024) & (Kilotons)
- Table 42. Middle East and Africa Pulmonary Drugs Sales by Region (2019-2024) & (Kilotons)
- Table 43. Sanofi SA Pulmonary Drugs Basic Information
- Table 44. Sanofi SA Pulmonary Drugs Product Overview
- Table 45. Sanofi SA Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 46. Sanofi SA Business Overview
- Table 47. Sanofi SA Pulmonary Drugs SWOT Analysis
- Table 48. Sanofi SA Recent Developments
- Table 49. Meda Pharmaceuticals Pulmonary Drugs Basic Information
- Table 50. Meda Pharmaceuticals Pulmonary Drugs Product Overview
- Table 51. Meda Pharmaceuticals Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 52. Meda Pharmaceuticals Business Overview
- Table 53. Meda Pharmaceuticals Pulmonary Drugs SWOT Analysis
- Table 54. Meda Pharmaceuticals Recent Developments
- Table 55. Circassia Pharmaceuticals Plc. Pulmonary Drugs Basic Information
- Table 56. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Overview
- Table 57. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 58. Circassia Pharmaceuticals Plc. Pulmonary Drugs SWOT Analysis
- Table 59. Circassia Pharmaceuticals Plc. Business Overview
- Table 60. Circassia Pharmaceuticals Plc. Recent Developments
- Table 61. AstraZeneca Plc. Pulmonary Drugs Basic Information
- Table 62. AstraZeneca Plc. Pulmonary Drugs Product Overview
- Table 63. AstraZeneca Plc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 64. AstraZeneca Plc. Business Overview
- Table 65. AstraZeneca Plc. Recent Developments
- Table 66. GlaxoSmithKline Plc. Pulmonary Drugs Basic Information

- Table 67. GlaxoSmithKline Plc. Pulmonary Drugs Product Overview
- Table 68. GlaxoSmithKline Plc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 69. GlaxoSmithKline Plc. Business Overview
- Table 70. GlaxoSmithKline Plc. Recent Developments
- Table 71. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Basic Information
- Table 72. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Overview
- Table 73. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 74. Mallinckrodt Pharmaceuticals Plc. Business Overview
- Table 75. Mallinckrodt Pharmaceuticals Plc. Recent Developments
- Table 76. Cheisi Farmaceutici S.p.A Pulmonary Drugs Basic Information
- Table 77. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Overview
- Table 78. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 79. Cheisi Farmaceutici S.p.A Business Overview
- Table 80. Cheisi Farmaceutici S.p.A Recent Developments
- Table 81. Zambon Company S.p.A Pulmonary Drugs Basic Information
- Table 82. Zambon Company S.p.A Pulmonary Drugs Product Overview
- Table 83. Zambon Company S.p.A Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 84. Zambon Company S.p.A Business Overview
- Table 85. Zambon Company S.p.A Recent Developments
- Table 86. Alaxia SAS Pulmonary Drugs Basic Information
- Table 87. Alaxia SAS Pulmonary Drugs Product Overview
- Table 88. Alaxia SAS Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 89. Alaxia SAS Business Overview
- Table 90. Alaxia SAS Recent Developments
- Table 91. Merck Sharp and Dohme Limited Pulmonary Drugs Basic Information
- Table 92. Merck Sharp and Dohme Limited Pulmonary Drugs Product Overview
- Table 93. Merck Sharp and Dohme Limited Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 94. Merck Sharp and Dohme Limited Business Overview
- Table 95. Merck Sharp and Dohme Limited Recent Developments
- Table 96. Boehringer Ingelheim Pulmonary Drugs Basic Information
- Table 97. Boehringer Ingelheim Pulmonary Drugs Product Overview
- Table 98. Boehringer Ingelheim Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

- Table 99. Boehringer Ingelheim Business Overview
- Table 100. Boehringer Ingelheim Recent Developments
- Table 101. Grifols Pulmonary Drugs Basic Information
- Table 102. Grifols Pulmonary Drugs Product Overview
- Table 103. Grifols Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 104. Grifols Business Overview
- Table 105. Grifols Recent Developments
- Table 106. S.A. Pulmonary Drugs Basic Information
- Table 107. S.A. Pulmonary Drugs Product Overview
- Table 108. S.A. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 109. S.A. Business Overview
- Table 110. S.A. Recent Developments
- Table 111. Abbott Laboratories Pulmonary Drugs Basic Information
- Table 112. Abbott Laboratories Pulmonary Drugs Product Overview
- Table 113. Abbott Laboratories Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 114. Abbott Laboratories Business Overview
- Table 115. Abbott Laboratories Recent Developments
- Table 116. AbbVie Inc. Pulmonary Drugs Basic Information
- Table 117. AbbVie Inc. Pulmonary Drugs Product Overview
- Table 118. AbbVie Inc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 119. AbbVie Inc. Business Overview
- Table 120. AbbVie Inc. Recent Developments
- Table 121. Aerogen Pharma Ltd. Pulmonary Drugs Basic Information
- Table 122. Aerogen Pharma Ltd. Pulmonary Drugs Product Overview
- Table 123. Aerogen Pharma Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 124. Aerogen Pharma Ltd. Business Overview
- Table 125. Aerogen Pharma Ltd. Recent Developments
- Table 126. Aurobindo Pharma Ltd. Pulmonary Drugs Basic Information
- Table 127. Aurobindo Pharma Ltd. Pulmonary Drugs Product Overview
- Table 128. Aurobindo Pharma Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 129. Aurobindo Pharma Ltd. Business Overview
- Table 130. Aurobindo Pharma Ltd. Recent Developments
- Table 131. Celon Pharma SA Pulmonary Drugs Basic Information

- Table 132. Celon Pharma SA Pulmonary Drugs Product Overview
- Table 133. Celon Pharma SA Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 134. Celon Pharma SA Business Overview
- Table 135. Celon Pharma SA Recent Developments
- Table 136. Cipla Ltd. Pulmonary Drugs Basic Information
- Table 137. Cipla Ltd. Pulmonary Drugs Product Overview
- Table 138. Cipla Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 139. Cipla Ltd. Business Overview
- Table 140. Cipla Ltd. Recent Developments
- Table 141. F. Hoffmann La Roche Ltd. Pulmonary Drugs Basic Information
- Table 142. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Overview
- Table 143. F. Hoffmann La Roche Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 144. F. Hoffmann La Roche Ltd. Business Overview
- Table 145. F. Hoffmann La Roche Ltd. Recent Developments
- Table 146. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Basic Information
- Table 147. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Overview
- Table 148. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 149. Glenmark Pharmaceuticals Ltd. Business Overview
- Table 150. Glenmark Pharmaceuticals Ltd. Recent Developments
- Table 151. Lupin Ltd. Pulmonary Drugs Basic Information
- Table 152. Lupin Ltd. Pulmonary Drugs Product Overview
- Table 153. Lupin Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 154. Lupin Ltd. Business Overview
- Table 155. Lupin Ltd. Recent Developments
- Table 156. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Basic Information
- Table 157. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Overview
- Table 158. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 159. Medisol Lifescience Pvt. Ltd. Business Overview
- Table 160. Medisol Lifescience Pvt. Ltd. Recent Developments
- Table 161. Novartis AG Pulmonary Drugs Basic Information
- Table 162. Novartis AG Pulmonary Drugs Product Overview
- Table 163. Novartis AG Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

- Table 164. Novartis AG Business Overview
- Table 165. Novartis AG Recent Developments
- Table 166. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Basic Information
- Table 167. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Overview
- Table 168. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 169. Sumitomo Pharma Co. Ltd. Business Overview
- Table 170. Sumitomo Pharma Co. Ltd. Recent Developments
- Table 171. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Basic Information
- Table 172. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Overview
- Table 173. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 174. Teva Pharmaceutical Industries Ltd. Business Overview
- Table 175. Teva Pharmaceutical Industries Ltd. Recent Developments
- Table 176. Vertex Pharmaceuticals Inc. Pulmonary Drugs Basic Information
- Table 177. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Overview
- Table 178. Vertex Pharmaceuticals Inc. Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 179. Vertex Pharmaceuticals Inc. Business Overview
- Table 180. Vertex Pharmaceuticals Inc. Recent Developments
- Table 181. Wellona Pharma Pulmonary Drugs Basic Information
- Table 182. Wellona Pharma Pulmonary Drugs Product Overview
- Table 183. Wellona Pharma Pulmonary Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
- Table 184. Wellona Pharma Business Overview
- Table 185. Wellona Pharma Recent Developments
- Table 186. Global Pulmonary Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
- Table 187. Global Pulmonary Drugs Market Size Forecast by Region (2025-2030) & (M USD)
- Table 188. North America Pulmonary Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
- Table 189. North America Pulmonary Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 190. Europe Pulmonary Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
- Table 191. Europe Pulmonary Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 192. Asia Pacific Pulmonary Drugs Sales Forecast by Region (2025-2030) & (Kilotons)

- Table 193. Asia Pacific Pulmonary Drugs Market Size Forecast by Region (2025-2030) & (M USD)
- Table 194. South America Pulmonary Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
- Table 195. South America Pulmonary Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 196. Middle East and Africa Pulmonary Drugs Consumption Forecast by Country (2025-2030) & (Units)
- Table 197. Middle East and Africa Pulmonary Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 198. Global Pulmonary Drugs Sales Forecast by Type (2025-2030) & (Kilotons)
- Table 199. Global Pulmonary Drugs Market Size Forecast by Type (2025-2030) & (M USD)
- Table 200. Global Pulmonary Drugs Price Forecast by Type (2025-2030) & (USD/Ton)
- Table 201. Global Pulmonary Drugs Sales (Kilotons) Forecast by Application (2025-2030)
- Table 202. Global Pulmonary Drugs Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Pulmonary Drugs
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Pulmonary Drugs Market Size (M USD), 2019-2030
- Figure 5. Global Pulmonary Drugs Market Size (M USD) (2019-2030)
- Figure 6. Global Pulmonary Drugs Sales (Kilotons) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Pulmonary Drugs Market Size by Country (M USD)
- Figure 11. Pulmonary Drugs Sales Share by Manufacturers in 2023
- Figure 12. Global Pulmonary Drugs Revenue Share by Manufacturers in 2023
- Figure 13. Pulmonary Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Pulmonary Drugs Average Price (USD/Ton) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Pulmonary Drugs Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Pulmonary Drugs Market Share by Type
- Figure 18. Sales Market Share of Pulmonary Drugs by Type (2019-2024)
- Figure 19. Sales Market Share of Pulmonary Drugs by Type in 2023
- Figure 20. Market Size Share of Pulmonary Drugs by Type (2019-2024)
- Figure 21. Market Size Market Share of Pulmonary Drugs by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Pulmonary Drugs Market Share by Application
- Figure 24. Global Pulmonary Drugs Sales Market Share by Application (2019-2024)
- Figure 25. Global Pulmonary Drugs Sales Market Share by Application in 2023
- Figure 26. Global Pulmonary Drugs Market Share by Application (2019-2024)
- Figure 27. Global Pulmonary Drugs Market Share by Application in 2023
- Figure 28. Global Pulmonary Drugs Sales Growth Rate by Application (2019-2024)
- Figure 29. Global Pulmonary Drugs Sales Market Share by Region (2019-2024)
- Figure 30. North America Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 31. North America Pulmonary Drugs Sales Market Share by Country in 2023

- Figure 32. U.S. Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 33. Canada Pulmonary Drugs Sales (Kilotons) and Growth Rate (2019-2024)
- Figure 34. Mexico Pulmonary Drugs Sales (Units) and Growth Rate (2019-2024)
- Figure 35. Europe Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 36. Europe Pulmonary Drugs Sales Market Share by Country in 2023
- Figure 37. Germany Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 38. France Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 39. U.K. Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 40. Italy Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 41. Russia Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 42. Asia Pacific Pulmonary Drugs Sales and Growth Rate (Kilotons)
- Figure 43. Asia Pacific Pulmonary Drugs Sales Market Share by Region in 2023
- Figure 44. China Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 45. Japan Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 46. South Korea Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 47. India Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 48. Southeast Asia Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 49. South America Pulmonary Drugs Sales and Growth Rate (Kilotons)
- Figure 50. South America Pulmonary Drugs Sales Market Share by Country in 2023
- Figure 51. Brazil Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 52. Argentina Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 53. Columbia Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 54. Middle East and Africa Pulmonary Drugs Sales and Growth Rate (Kilotons)
- Figure 55. Middle East and Africa Pulmonary Drugs Sales Market Share by Region in 2023
- Figure 56. Saudi Arabia Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 57. UAE Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 58. Egypt Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 59. Nigeria Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 60. South Africa Pulmonary Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
- Figure 61. Global Pulmonary Drugs Sales Forecast by Volume (2019-2030) & (Kilotons)
- Figure 62. Global Pulmonary Drugs Market Size Forecast by Value (2019-2030) & (M USD)
- Figure 63. Global Pulmonary Drugs Sales Market Share Forecast by Type (2025-2030)
- Figure 64. Global Pulmonary Drugs Market Share Forecast by Type (2025-2030)

Figure 65. Global Pulmonary Drugs Sales Forecast by Application (2025-2030)

Figure 66. Global Pulmonary Drugs Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Pulmonary Drugs Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G774C055964FEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G774C055964FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970